Literature DB >> 9322534

Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis.

L Pensati1, A Costanzo, A Ianni, D Accapezzato, R Iorio, G Natoli, R Nisini, C Almerighi, C Balsano, P Vajro, A Vegnente, M Levrero.   

Abstract

Inherited mutations of the Fas/Apo1/CD95 gene, a cell-surface receptor involved in cell death signaling and in the control of self-reactivity, characterize the recently identified autoimmune lymphoproliferative syndromes. A patient with type 2 autoimmune hepatitis with the immunologic and genetic features of autoimmune lymphoproliferative syndrome is described. The clinical picture was dominated by liver disease with hepatosplenomegaly and positivity for anti-liver-kidney microsome 1 and anti-liver-cytosol 1 antibodies. A marked increase in CD3+CD4-CD8-T lymphocytes and inherited mutations in Fas alleles that led to the expression of a soluble form of the protein were also found. Fas-mediated apoptosis was deficient in the patient as it was in her mother and her sister, who carried the same allele 2 mutation. This observation links type 2 autoimmune hepatitis, an organ-specific disease, with a genetically determined defect in peripheral tolerance control.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322534     DOI: 10.1053/gast.1997.v113.pm9322534

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

Review 1.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

2.  Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.

Authors:  C E Jackson; R E Fischer; A P Hsu; S M Anderson; Y Choi; J Wang; J K Dale; T A Fleisher; L A Middelton; M C Sneller; M J Lenardo; S E Straus; J M Puck
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

Review 3.  CD95-mediated cell signaling in cancer: mutations and post-translational modulations.

Authors:  Sébastien Tauzin; Laure Debure; Jean-François Moreau; Patrick Legembre
Journal:  Cell Mol Life Sci       Date:  2011-11-01       Impact factor: 9.261

4.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.

Authors:  D S Vinay; B S Kwon
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

Review 5.  Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management.

Authors:  Jutte van der Werff ten Bosch
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas.

Authors:  Irina Bonzheim; Eva Geissinger; Wen-Yu Chuang; Sabine Roth; Philipp Ströbel; Alexander Marx; Peter Reimer; Martin Wilhelm; Bernhard Puppe; Andreas Rosenwald; Hans Konrad Müller-Hermelink; Thomas Rüdiger
Journal:  J Hematop       Date:  2008-04-24       Impact factor: 0.196

7.  Inhibition of intracellular peroxides and apoptosis of lymphocytes in lupus-prone B/W mice by dietary n-6 and n-3 lipids with calorie restriction.

Authors:  C P Reddy Avula; Richard A Lawrence; Khaliquz Zaman; Gabriel Fernandes
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

8.  The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations.

Authors:  A K Vaishnaw; J R Orlinick; J L Chu; P H Krammer; M V Chao; K B Elkon
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

9.  Clustering of distinct autoimmune diseases associated with functional abnormalities of T cell survival in children.

Authors:  C Pignata; M Alessio; U Ramenghi; S Bonissoni; D Difranco; A Brusco; E Matrecano; A Franzese; I Dianzani; U Dianzani
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

10.  Precise mapping of the CD95 pre-ligand assembly domain.

Authors:  Valérie Edmond; Benoist Ghali; Aubin Penna; Jean-Luc Taupin; Sophie Daburon; Jean-François Moreau; Patrick Legembre
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.